[go: up one dir, main page]

UY30543A1 - Formulacion de aerosol para la inhalacion de beta- agonistas - Google Patents

Formulacion de aerosol para la inhalacion de beta- agonistas

Info

Publication number
UY30543A1
UY30543A1 UY30543A UY30543A UY30543A1 UY 30543 A1 UY30543 A1 UY 30543A1 UY 30543 A UY30543 A UY 30543A UY 30543 A UY30543 A UY 30543A UY 30543 A1 UY30543 A1 UY 30543A1
Authority
UY
Uruguay
Prior art keywords
inhalation
agonists
beta
aerosol formulation
formulation
Prior art date
Application number
UY30543A
Other languages
English (en)
Inventor
Rainer Weitzel
Kirsten Radau
Michael Aven
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY30543A1 publication Critical patent/UY30543A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una formulacion en aereosol libre de gas propulsor que contiene uno o varios compuestos de la formula general 1, en donde los radicales R1, R2, R3 y X- pueden tener los significados mencionados en las reivindicaciones y en la descripcion, y otro principio activo 2, para la inhalacion.
UY30543A 2006-08-18 2007-08-15 Formulacion de aerosol para la inhalacion de beta- agonistas UY30543A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119129 2006-08-18
EP07101128 2007-01-25

Publications (1)

Publication Number Publication Date
UY30543A1 true UY30543A1 (es) 2008-03-31

Family

ID=39082381

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30543A UY30543A1 (es) 2006-08-18 2007-08-15 Formulacion de aerosol para la inhalacion de beta- agonistas

Country Status (17)

Country Link
US (1) US20080041370A1 (es)
EP (1) EP2054034A2 (es)
JP (1) JP2010501021A (es)
KR (1) KR20090040922A (es)
AR (1) AR062424A1 (es)
AU (1) AU2007285746A1 (es)
BR (1) BRPI0715692A2 (es)
CA (1) CA2660480A1 (es)
CO (1) CO6150123A2 (es)
EA (1) EA200900267A1 (es)
IL (1) IL197024A0 (es)
MX (1) MX2009001553A (es)
NO (1) NO20090410L (es)
PE (1) PE20080607A1 (es)
TW (1) TW200817010A (es)
UY (1) UY30543A1 (es)
WO (1) WO2008020056A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
DK1917253T3 (da) * 2005-08-15 2015-03-30 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af betamimetika
BR112014003061A2 (pt) 2011-08-12 2017-02-21 Boehringer Ingelheim Vetmedica Gmbh composição farmacêutica com sabor mascarado
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
WO2014096116A1 (en) 2012-12-21 2014-06-26 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical formulation comprising ciclesonide
BR112015010842B1 (pt) * 2012-12-21 2021-03-30 Boehringer Ingelheim Vetmedica Gmbh Uso da ciclesonida para o tratamento de doença das vias respiratórias em cavalos
US9944618B2 (en) 2013-03-14 2018-04-17 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
RS59613B1 (sr) 2014-06-18 2020-01-31 Boehringer Ingelheim Vetmedica Gmbh Muskarinski antagonisti i njihove kombinacije za lečenje bolesti disajnih puteva kod konja
JP7189766B2 (ja) 2015-10-09 2022-12-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング マイクロ構造コンポーネントのコーティング方法
CN115397417A (zh) * 2020-04-16 2022-11-25 广州谷森制药有限公司 含有噻托溴铵和奥达特罗的可吸入溶液制剂
US20210322309A1 (en) * 2020-04-16 2021-10-21 Cai Gu Huang Inhalable Formulation of a Solution Containing Olodaterol
WO2021262648A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol and budesonide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
NZ550797A (en) * 2004-04-22 2010-08-27 Boehringer Ingelheim Int Pharmaceutical combinations containing 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one for treating respiratory diseases
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten

Also Published As

Publication number Publication date
BRPI0715692A2 (pt) 2013-08-06
CO6150123A2 (es) 2010-04-20
JP2010501021A (ja) 2010-01-14
NO20090410L (no) 2009-03-02
WO2008020056A2 (de) 2008-02-21
EP2054034A2 (de) 2009-05-06
PE20080607A1 (es) 2008-07-17
KR20090040922A (ko) 2009-04-27
AR062424A1 (es) 2008-11-05
WO2008020056A3 (de) 2008-09-12
AU2007285746A1 (en) 2008-02-21
CA2660480A1 (en) 2008-02-21
US20080041370A1 (en) 2008-02-21
TW200817010A (en) 2008-04-16
MX2009001553A (es) 2009-04-17
IL197024A0 (en) 2009-11-18
EA200900267A1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
UY30543A1 (es) Formulacion de aerosol para la inhalacion de beta- agonistas
ECSP088294A (es) Formulación en aerosol para la inhalación de beta-agonistas
UY30542A1 (es) Formulacion de aerosol para la inhalacion de agonistas beta
DOP2010000191A (es) Derivados bis-(sulfonilamino)
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CR9081A (es) Inhibidores de la interaccion entre mdm2 y p53
CO6270311A2 (es) Derivados bis-(sulfonilamino) en terapia 066
UY30327A1 (es) Nuevos compuestos ii
TW200833324A (en) Sulfonamide derivatives
UY30789A1 (es) Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
IL187409A0 (en) Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l- cpt1) inhibitors
UY31349A1 (es) Inhibidores de la interaccion entre mdm2 y p53
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
UY30520A1 (es) Compuestos de pirimidina
CR9268A (es) Nuevo derivado de diazabiciclononeno
ECSP066947A (es) Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
AR063027A1 (es) Derivados de sulfonamida
UY30552A1 (es) Combinaciones farmacologiicas en base a derivados sustituidos de la n-(5-{2-[1,1-dimetil-propilamino]-1-hidroxi-metil}-2-hidroxi-fenil)-metansulfonamida y aplicaciones
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
UY28891A1 (es) Formulacion en aerosol para la inhalacion de beta-agonistas
UY30555A1 (es) Formulacion aerosol para la inhalacion de beta-agonistas
NO20081587L (no) Aerosolformulering for inhalering

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170725